Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Sacituzumab Tirumotecan for Previously Treated Locally Advanced or Metastatic Pancreatic Cancer

NCT07561463 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT07561463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07561463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Sacituzumab Tirumotecan for Previously Treated Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
July 1, 2027
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)